Understand the source comparison
Semax Amidate Optic Nerve Disease: Mechanism Comparison
Understanding how Semax Amidate's neuroprotective mechanisms compare to other investigational agents helps clarify its potential role in optic nerve disease research and highlights gaps in the current evidence base. Semax Amidate BDNF upregulation, PI3K/Akt ac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how Semax Amidate's neuroprotective mechanisms compare to other investigational agents helps clarify its potential role in optic nerve disease research and highlights gaps in the current evidence base.
- Semax Amidate
- BDNF upregulation, PI3K/Akt activation, oxidative stress reduction
- 2.2-fold improvement in crush models; 35–40% in chronic IOP elevation models
- Intranasal or subcutaneous
- No human optic nerve disease trials published
- Promising preclinical data, but zero human evidence for optic nerve protection
- Brimonidine
- α2-adrenergic agonist; NMDA receptor antagonism, antiapoptotic signaling
- 1.5–1.8-fold improvement in crush and IOP models
- Topical ophthalmic
- Phase III trials for glaucoma (LOW-PRESSURE trial) showed no RGC protection benefit beyond IOP lowering
- Widely available as IOP-lowering drug; neuroprotection hypothesis not confirmed in humans
- Citicoline (oral)
- Enhances phospholipid synthesis, mitochondrial function
- 1.3–1.5-fold improvement in ischemia models
- Oral
- Phase II/III trials (LALES) showed marginal RNFL thickness preservation but no functional (visual field) benefit
- Human data exists but lacks robust clinical efficacy signal brimonidine-like
- BDNF (recombinant protein)
- Direct TrkB receptor activation
- 3.0–4.0-fold improvement in crush and axotomy models
- Intravitreal injection
- No active optic nerve trials; poor bioavailability limits clinical use
- Gold-standard mechanism but impractical delivery and short half-life prevent clinical translation
- Memantine
- NMDA receptor antagonist, reduces excitotoxicity
- 1.4–1.6-fold improvement in ischemia and IOP models
- Phase III glaucoma trial (2015) failed primary endpoint; no benefit on visual field progression
- Mechanism sound but human RCT showed no efficacy
- Semax Amidate sits in a category with strong biological rationale and animal model efficacy but zero human clinical trial data specifically for optic nerve disease. Its closest mechanistic relative. Recombinant BDNF. Shows even stronger RGC protection in animal models but has never advanced to clinical trials due to delivery challenges (intravitreal injections required; protein half-life < 10 minutes in vitreous). Semax Amidate's intranasal route and extended half-life theoretically solve the delivery problem, but no Phase I safety study in glaucoma or optic neuropathy patients has been published as of 2026.